Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Clears Omnitrope; Product Is Not The Process, But Nor Is It A Pathway

Executive Summary

Sandoz' approval for the first follow-on version of a human growth hormone product relies on data from a Phase III clinical program that studied 89 pediatric patients

You may also be interested in...

Biosimilar Pricing: Sandoz Vows Not To Make Omnitrope ‘Mistake’ With Filgrastim

Sandoz, Hospira execs say U.S. payers and consumers will ‘not be disappointed’ in cost savings from products approved under the 351(k) pathway, but warn that price alone may not tell whole story.

Mylan’s Biogenerics Strategy: Build Standards From Europe, Be Financially Cautious

Generic firm is counting on Global Biologics Head Patrick Vink’s experience as Sandoz biopharma head to lead the firm into the follow-on biologics marketplace.

Omnitrope’s Improved Delivery System Already Getting Formulary Traction

Sandoz sued FDA in its effort to win approval of Omnitrope (somatropin [rDNA origin]). Now the company is using more mundane regulatory procedures as it works to expand sales of its follow-on human growth hormone

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts